FDA Approves First At-Home Alzheimer's Treatment

For the first time ever, people with early Alzheimer's can start treatment in the comfort of their own homes instead of making weekly trips to an infusion center.

The FDA approved LEQEMBI IQLIK in July 2026, a groundbreaking autoinjector that delivers the same amyloid-fighting medicine as IV infusions but takes only 15 seconds per shot. Patients give themselves two quick injections once a week, and studies show it works just as well as the hospital version.

This matters because Alzheimer's affects over 6 million Americans, and early treatment can slow cognitive decline. But getting to an infusion center every week creates a huge burden for patients and their caregivers, who often struggle with memory issues, transportation, and managing busy schedules. Many give up before they even start.

The new autoinjector changes everything. In studies, 94% of patients and caregivers found the device easy to use at home. Clinical trials showed the subcutaneous version removes brain plaques just as effectively as IV treatment, with similar safety profiles and no increase in serious side effects.

Patients can now choose how they want to receive treatment throughout their entire journey. They can start with the at-home injections, switch to IV if needed, or go back to self-injections later. This flexibility means more people can actually access and stick with treatment.

The approval comes from comprehensive data including the Phase 3 Clarity AD study, which followed patients through 18 months of treatment. Results showed once-weekly subcutaneous doses achieved the same drug exposure as IV infusions, supporting identical clinical benefits and amyloid removal.

The Ripple Effect

This innovation frees up precious infusion center capacity for patients who truly need it while reducing the strain on healthcare systems. Fewer clinic visits means less time off work for caregivers, lower transportation costs, and more independence for patients in the earliest stages of disease.

The convenience factor could dramatically improve treatment adherence, a major challenge with chronic conditions. When taking your medicine is simpler, people are more likely to stay on track.

Eisai and Biogen plan to launch LEQEMBI IQLIK for initiation dosing in late August 2026, with patient assistance programs available for those who need financial support. The device will be available through specialty pharmacies nationwide.

A new era of Alzheimer's care just moved from the hospital to the living room, putting patients back in control.

#